I n this issue of Circulation, Koval et al 1 show that 2 arrhythmogenic human cardiac Na ϩ channel (hNa V 1.5) variants mimic the altered channel gating effects induced by Ca 2ϩ -calmodulin-dependent protein kinase (CaMKII). They also show that phosphorylation of an adjacent CaMKII target site on Na V 1.5 is enhanced in human heart failure (HF) samples and in the border zone of postinfarcted canine hearts.
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The cardiac Na ϩ channel, Na V 1.5, is responsible for inward Na ϩ current (I Na ) that drives the cardiac action potential (AP) upstroke and electrical impulse propagation. 2 Genetic variants of the SCN5A gene encoding Na V 1.5 are associated with long QT syndrome-3 (LQTs; gain of function), Brugada syndrome (BRs; loss of function), conduction system disease, sudden infant death syndrome, sick sinus syndrome, and dilated cardiomyopathy. 3, 4 These inherited channelopathies have been tremendously important to our understanding of normal Na V 1.5 function and arrhythmia mechanisms. However, acquired forms of altered Na V 1.5 function attributable to posttranslational modification (eg, phosphorylation or oxidation) may have pathophysiological consequences during ischemia/reperfusion or HF and thus reach a larger patient population. Indeed, half of all HF deaths are sudden and presumed to be attributable to lethal ventricular arrhythmias. 5, 6 The pore forming ␣ subunit (Na V 1.5; Ϸ220 Kd predicted MW) has 4 homologous domains (I-IV) with 6 transmembrane segments each (S1-S6; Figure 1 ), is glycosylated, and has auxiliary regulatory ␤ subunits (␤1-␤4; Ϸ30 -35 Kd). 7 The S5-S6 linker includes the P-loops or pore region, the 4 S4 segments serve as voltage sensors (involved in activation gating), whereas an IFM motif in the DIII-IV linker is important for fast inactivation gating. Importantly, Na V 1.5 forms a macromolecular complex with interacting proteins that can regulate channel gating and localization, and mutations in many of these proteins can be proarrhythmic (reviewed in 3, 7, 8 ).
CaMKII Regulation of Cardiac Na ؉ Channels
CaMKII was shown to associate with and phosphorylate Na V 1.5, causing characteristic I Na gating changes in mouse and rabbit ventricular myocytes. 9 Specifically, CaMKII shifted I Na availability to more negative potentials, enhanced entry into intermediate inactivation, and slowed recovery from inactivation, all of which are loss-of function effects (analogous to BRs). CaMKII also increased late I Na (I NaL ), an acquired LQTs gain-of-function effect. These potentially arrhythmogenic I Na effects were acutely abolished by CaM-KII inhibitors KN93 or AIP in rabbit myocytes. CaMKII expression and activity are both increased in HF, 10, 11 and CaMKII␦ overexpressing mice exhibit enhanced arrhythmogenesis. 9 Notably, the full set of CaMKII-induced changes in I Na gating almost exactly phenocopies a human point mutation (Ins1795D in the C terminus) that is linked with combined LQTs and BRs in the same patients. 12 In these contexts, the seminal Wagner et al 9 study fueled the search for critical CaMKII target sites on Na V 1.5 that could explain these gating effects and identify potential therapeutic targets for arrhythmias in cardiac disease.
Based on the above, one might look for a CaMKII target site in the C-terminal tail (near residue 1795), but Aiba et al 13 provided evidence that the I-II loop might be a major CaMKII phosphorylation target. Using a computer-based scan for the traditional CaMKII consensus sequence, RXXS/T, Hund et al 14 identified S571 as a potential CaMKII target ( Figure 1 ). They demonstrated that CaMKII phosphorylates S571 in vitro and that, in a heterologous cell system expressing Na V 1.5, CaMKII shifts WT steady state inactivation to negative potentials. This effect on channel inactivation was abolished when S571 was mutated to a nonphosphorylatable alanine and mimicked when S571 was mutated to a phosphomimetic glutamine reside. Our group 15 found that only the I-II loop of hNa V 1.5 was substantially phosphorylated by CaMKII (ie, neither other loops nor N-or C-tail were targets), and systematic analysis of the entire I-II loop showed that S516 and T594 were the main in vitro CaMKII phosphorylation sites. In patch-clamp analysis, we found that alanine substitution of S516, S571, and T594 could all inhibit the CaMKII-dependent negative shift in I Na availability and accumulation of intermediate inactivation observed in myocytes. However, only S516E and T594E phosphomimetic mutants could recapitulate CaMKII effects on I Na availability. Thus there may be 3 sites in this stretch of the I-II loop that participate in CaMKII-dependent regulation of cardiac I Na gating (Figure 1 ).
There are 2 major points raised by Koval et al 1 in extending their work on the S571 site. First, they provide evidence that phosphorylation of S571 on Na V 1.5 is increased in the canine postinfarct border zone, may be slightly increased in human HF, and is increased in isolated mouse myocytes after acute stress (isoproterenol ϩ phosphatase inhibition) but not in mice expressing CaMKII inhibitor AC3-I. These observations have potentially important implications for the genesis of acquired arrhythmias in cardiac disease. Second, they show that 2 rare, naturally occurring Na V 1.5 point mutations (A572D and Q573E) might functionally mimic the negative charge induced by S571 phosphorylation, resulting in similar channel biophysics. Although these experiments only indirectly suggest this mimicry, electrostatic potential maps are also consistent with this idea. These channels also evoked AP prolongation in cultured neonatal mouse ventricular myocytes. The authors thus posit that the region comprising residues 571 to 573 functions as a sort of negatively charged hot spot, with a negative charge at any of these 3 residues (resulting from phosphorylation or a naturally occurring mutation) conferring similar results on channel gating and function. The 571 to 573 hot spot referred to here could extend to encompass the other CaMKII modulation sites (S516 and T594), which may also have a local charge basis such that multiple local sites might contribute to altered I Na gating. Importantly, this may provide a new therapeutic target downstream of CaMKII for heart failure and arrhythmias. 16 Further studies will be required to clarify these molecular mechanisms.
CaMKII and Arrhythmias in HF
CaMKII transgenic mice exhibit tachyarrhythmias, 9 and CaMKII inhibition may be protective against electrical 17 and structural 18 remodeling in HF. Interestingly, heterozygous SCN5A ϩ/Ϫ knock-out 19 and Ins1795D knock-in 20 mice also have conduction disturbances and increased propensity to arrhythmias. Because CaMKII can cause both LQTs-like I NaL and loss-of-function BRs-like effects, 3, 4 it is worth considering how CaMKII effects contribute to arrhythmogenesis and increase the risk of SCD in HF. Channelopathies associated with Na V 1.5 loss of function, such as BRs, and gain of function, LQT3, provide a nice framework for discussion. Figure 1 . CaMKII phosphorylation of NaV1.5 is proarrhythmogenic. Arrhythmogenic mechanism of CaMKII-based regulation of I Na , showing different CaMKII-based alterations in cardiac ion channel targets and contributions. The emphasis is on CaMKII sites on Na V 1.5 at S571, S516, and T594 on the DI-II loop of Na V 1.5. When loss-and gainof-function effects combine with other CaMKII ion channel targets, this can further enhance ventricular arrhythmias and sudden cardiac death.
Koval et al 1 found that A572D and Q573E arrhythmia variants expressed in cultured neonatal mouse cardiomyocytes exhibited enhanced I NaL and action potential duration that was sensitive to tetrodotoxin and the I NaL -specific inhibitor Ranolazine. Early afterdepolarizations were even seen in 2 of the 9 A572D neonatal mouse myocytes, and their computer simulations produced comparable results and resemble earlier LQT3 models of I NaL effect gain-of-function mutations in SCN5A. 21 In our computational model of CaMKII effects on I Na in rabbit, 22 an LQT3-like phenotype was present at low heart rates (where APD is long) and thus integrated I NaL is large. At higher heart rates (Ͼ1Hz), the APD effect disappeared, and a BRs-like loss of I Na availability and slower AP rate of rise was more apparent. Several studies have demonstrated increased I NaL in HF, 23, 24 and some of this may be dependent on CaMKII activity. 25 More mechanistic work will be needed to test which (if any) of the CaMKII phosphorylation sites is critical for enhanced I NaL . Regardless, selective I NaL inhibition may be an important therapeutic strategy to treat some LQT-like arrhythmias in HF. 26 What about the I Na loss-of-function effects caused by CaMKII? CaMKII and all of the identified CaMKII sites (S571, T594, and S516) seem to mediate loss of I Na function effects (reduced I Na availability, increased intermediate inactivation, and slowed recovery from inactivation). These effects may also contribute to arrhythmogenesis analogous to BRs but have attracted less attention than the I NaL and LQT3-like effects. The loss of I Na function induced by CaMKII is likely to be exacerbated at high heart rates 22 and could slow conduction, create conduction block in vulnerable tissue, shorten APD, and enhance the substrate for reentrant arrhythmias (Figure 1) . In that sense, the CaMKII effects would match the Ins1795D and ⌬K1500 human mutations, where patients exhibit LQT symptoms at low heart rate and Brugada-like symptoms at high heart rate. 12, 27 
CaMKII Effects on Other Channels Contribute to Arrhythmias
CaMKII also modulates I Ca and I to and I K1 properties 16 (Figure 1 ). CaMKII mediates I Ca facilitation, which enhances peak I Ca and slows inactivation (gain-of-function) and tends to prolong APD (along with I NaL ), favoring early afterdepolarizations. CaMKII also enhances I to recovery from inactivation, thereby hastening repolarization. When the CaMKII effects on I Ca , I to , and I Na are combined, APD shortening is predicted in epicardial rabbit myocytes. 22 However, in endocardial or HF myocytes, with reduced I to expression and function, APD would be prolonged because of I Na and I Ca effects. This would enhance the normal transmural dispersion of repolarization, thereby enhancing the substrate for reentrant arrhythmias. Additionally, regional differences in CaM-KII activity, such as around myocardial infarct zones, may translate into heterogeneity of phosphorylated channels. Reentrant arrhythmias could thus ensue as in BRs. Clearly the combined effects of CaMKII in cardiac electric remodeling are complex, and further studies are needed. CaMKII also phosphorylates phospholamban (PLN) to stimulate SR Ca-ATPase (enhancing SR Ca 2ϩ loading) and the SR Ca 2ϩ release channel (RyR2) enhancing arrhythmogenic spontaneous SR Ca 2ϩ release. 16 Moreover, when the putative RyR2 CaMKII phosphorylation is mimicked (S2814D) or prevented (S2814A) in knock-in mice, there is increased or decreased (respectively) DADs and triggered arrhythmias. 28 Indeed, the combination of enhanced SR Ca 2ϩ uptake and sensitized RyR2 may synergize in developing CaMKII-dependent DADs. In the setting of HF, where Na/Ca exchange is increased and I K1 is reduced (both of which increase DAD amplitude), there is an increased propensity for triggered arrhythmias. 29 All of the above pathways could degenerate into lethal ventricular tachyarrhythmias (Figure 1 ). These mechanisms are certainly not mutually exclusive, and a mixture of several factors plays a role. Inherited mutations at Ins1795D and ⌬K1500 in hNa V 1.5 with combined LQTs and BRs and RyR2 sensitizing inherited mutations linked to catecholaminergic polymorphic ventricular tachycardia (CPVT), both of which phenocopy CaMKII effects, may identify these channel targets as especially important.
Future Studies
Koval et al 1 further our understanding of the role and importance of CaMKII-based Na V 1.5 phosphorylation at S571, but several key questions remain. What is the relative role of S571 and the other two CaMKII phosphorylation sites S516 and T594 (additive, synergistic, redundant, antagonistic)? Differences in the mode or location of CaMKII activation could differentially influence targets and their impact. For example, binding of CaMKII to ␤-spectrin may enhance site phosphorylation, 14 and activation state of CaM-KII may alter its binding affinities for certain substrates. 30 Further studies are needed to evaluate the multiple phosphorylatable CaMKII sites on the Na ϩ channel.
Going forward, it will be valuable to understand CaMKII effects on other Na ϩ channel isoforms (Figure 2 ), some of which may be expressed in the heart (Na V 1.1, 1.3, and 1.6). 8 The S571 and T594 CaMKII phospho-sites are well conserved among mammalian Na V 1.5 (and in chicken). The S516 phospho-site, in contrast, appears to be exclusive to human Na V 1.5 (in others there is no basic residue at the important P-3 position, except in rabbit). Skeletal muscle Na V 1.4 (SCN4A) has none of these phosphorylation sites. Some neuronal Na ϩ channels (SCN1A, 2A, 8A, and 9A or Na V 1.1, 1.2, 1.6, and 1.7) contain the S571 site, but the T594 site is only the same in SCN8A (Na V 1.6). This opens up new avenues of study about potential roles of CaMKII-dependent regulation of Na ϩ channels.
It will also be important to understand which CaMKII channel targets are the most important arrhythmogenic influences (among Na ϩ , K ϩ , and Ca 2ϩ channels or RyR2). Furthermore, studies are needed to determine whether different populations of, for example, Na ϩ channels are present even within the same myocyte that differ in their signaling interactions and regulation by CaMKII. It may also be important to test whether these sites are targeted by other kinases relevant to cardiac pathophysiology, such as protein kinase A and protein kinase C. Although much work remains to fully understand the complexities of phospho-regulation of voltage gated Na ϩ channels, the work from Koval et al 1 is an important step forward in our understanding of this process and its relevance to cardiac disease.
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